Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05546723 · ClinicalTrials.gov registry record · Phase 1
LMY-920 for Treatment of Relapsed or Refractory Myeloma
A Phase 1 study of Multiple Myeloma in Relapse and Multiple Myeloma, Refractory, sponsored by Luminary Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT05546723: Recruiting Phase 1 study of Multiple Myeloma in Relapse and Multiple Myeloma, Refractory, sponsored by Luminary Therapeutics.
NCT05546723 is a Phase 1 study of Multiple Myeloma in Relapse and Multiple Myeloma, Refractory that is actively recruiting participants, run by Luminary Therapeutics. The registered enrollment target is 30 participants, below the 49-participant average among 12 other Multiple Myeloma in Relapse trials with a reported enrollment target (39% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05546723, a Phase 1 study of Multiple Myeloma in Relapse and Multiple Myeloma, Refractory, is actively recruiting participants, sponsored by Luminary Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
Since CAR-T cell treatment of refractory myeloma has shown success, based on preclinical data, we posit that CAR-T cells expressing B-cell activating factor (BAFF) can become another strategy to treat refractory myeloma, even after relapse following BCMA targeting CAR-T cell treatment. This will be phase 1 study of BAFF ligand CAR-T cells in relapsed and refractory myeloma.
Primary Outcome
Maximum tolerated dose
Conditions Studied
Interventions
- BIOLOGICAL Autologous CAR-T cell therapy expressing the BAFF-ligand.
Study Locations (1)
Ohio
- University Hospitals Seidman Cancer Center - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2024-03-13 |
| Est. Completion | 2025-10-31 |
| Phase | Phase 1 |
What NCT05546723 shows while recruiting
NCT05546723 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 49-participant average among 12 other Multiple Myeloma in Relapse trials with a reported enrollment target (39% lower).
The record links to 2 conditions, with Multiple Myeloma in Relapse appearing as the primary indexed condition, and to 1 intervention - of which Autologous CAR-T cell therapy expressing the BAFF-ligand. is the first listed.
NCT05546723 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT05546723 about?
NCT05546723 is a clinical study titled "LMY-920 for Treatment of Relapsed or Refractory Myeloma". Since CAR-T cell treatment of refractory myeloma has shown success, based on preclinical data, we posit that CAR-T cells expressing B-cell activating factor (BAFF) can become another strategy to treat refractory myeloma, even after relapse following BCMA targeting CAR-T cell treatment. This will be ...
What is the current status of trial NCT05546723?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2024-03-13. Estimated completion is 2025-10-31.
What conditions does trial NCT05546723 study?
This clinical trial studies the following conditions: Multiple Myeloma in Relapse, Multiple Myeloma, Refractory.
What interventions are being tested in trial NCT05546723?
The interventions under investigation include: Autologous CAR-T cell therapy expressing the BAFF-ligand. (BIOLOGICAL).
Who is sponsoring clinical trial NCT05546723?
This trial is sponsored by Luminary Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05546723 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma in Relapse
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05546723's enrollment target sits among peer trials
30 6th of 12 higher than 6 of 12 other Multiple Myeloma in Relapse trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Myeloma in Relapse trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
TriPRIL CAR T Cells in Multiple Myeloma
RECRUITING · Phase 1
-
A Trial of Selinexor, Ruxolitinib and Methylprednisolone
RECRUITING · Phase 1
-
Ixazomib + Pomalidomide + Dexamethasone In MM
ACTIVE NOT RECRUITING · Phase 1
-
Study of HPN217 in Participants With Relapsed/Refractory Multiple Myeloma MK-4002 (MK-4002-001)
ACTIVE NOT RECRUITING · Phase 1
-
Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma
COMPLETED · Phase 1
-
A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI